https://pharma.industry-focus.net/home-1.feed 2024-04-28T16:44:32+00:00 Joomla! - Open Source Content Management 2013-12-20T06:00:41+00:00 2013-12-20T06:00:41+00:00 https://pharma.industry-focus.net/technology-trends/271-ict-receives-grant-for-brucellosis-vaccine.html Administrator [email protected]

<div class="feed-description"> <p> Institute of Chemical Technology (ICT), Mumbai has received a prestigious grant from Bill & Melinda Gates Foundation to develop the first green nanovaccine for nasal immunization against brucellosis. Prof. Vandana Patravale, ICT, Matunga was awarded USD100,000 in phase I of Grand Challenges Explorations Round 11 for developing the cost-effective vaccine technology from over 2700 applications. The sub-unit nanovaccine aims to confer long term protective immunity to humans and livestock population. Currently, Brucellosis is a zoonotic bacterial infection with a potential to be exploited as a bioweapon, and currently no human vaccine is available for treatment</p> </div>

<div class="feed-description"> <p> Institute of Chemical Technology (ICT), Mumbai has received a prestigious grant from Bill & Melinda Gates Foundation to develop the first green nanovaccine for nasal immunization against brucellosis. Prof. Vandana Patravale, ICT, Matunga was awarded USD100,000 in phase I of Grand Challenges Explorations Round 11 for developing the cost-effective vaccine technology from over 2700 applications. The sub-unit nanovaccine aims to confer long term protective immunity to humans and livestock population. Currently, Brucellosis is a zoonotic bacterial infection with a potential to be exploited as a bioweapon, and currently no human vaccine is available for treatment</p> </div> 2013-10-18T10:12:58+00:00 2013-10-18T10:12:58+00:00 https://pharma.industry-focus.net/technology-trends/269-novo-norsdik-plans-tresiba-a-insulin-degludec-in-india.html Administrator [email protected]

<div class="feed-description">Novo Norsdik, a Denmark based global healthcare organization is based in India. The company plans to launch 'Tresiba' a long lasting insulin injection in India. The drug used for Type I and Type II diabetes is likely to be available by end of 2013. It is once-daily injection and will be long acting till 42 hours, thereby providing patients enough time to manage the disease. Tresiba will be available in pre-filled pen enabling does upto 80 units in a single injection. </div>

<div class="feed-description">Novo Norsdik, a Denmark based global healthcare organization is based in India. The company plans to launch 'Tresiba' a long lasting insulin injection in India. The drug used for Type I and Type II diabetes is likely to be available by end of 2013. It is once-daily injection and will be long acting till 42 hours, thereby providing patients enough time to manage the disease. Tresiba will be available in pre-filled pen enabling does upto 80 units in a single injection. </div> 2013-10-18T10:13:56+00:00 2013-10-18T10:13:56+00:00 https://pharma.industry-focus.net/technology-trends/270-roselabs-to-manufacture-pre-filled-syringes-in-india.html Administrator [email protected]

<div class="feed-description"><p>Roselabs Bioscience Ltd and Roselabs Polymers Ltd is planning to invest Rs. 4000 million to manufacture pre-filled syringes in India. The method of using pre-filled syringe is designed to provide assured sterility, safety, convenience, greater accuracy, minimal over-filling, least medical waste, freedom from needle phobia and least chances of accidental needle stick injuries. The company has the capacity to manufacture 8 lakh syringes daily. Currently, 95% of pre-filled syringes are imported.</p> <b>Latest News : </b> <p>The company is in the process of raising Rs. 1000 million towards private equity placements and venture capital </p></div>

<div class="feed-description"><p>Roselabs Bioscience Ltd and Roselabs Polymers Ltd is planning to invest Rs. 4000 million to manufacture pre-filled syringes in India. The method of using pre-filled syringe is designed to provide assured sterility, safety, convenience, greater accuracy, minimal over-filling, least medical waste, freedom from needle phobia and least chances of accidental needle stick injuries. The company has the capacity to manufacture 8 lakh syringes daily. Currently, 95% of pre-filled syringes are imported.</p> <b>Latest News : </b> <p>The company is in the process of raising Rs. 1000 million towards private equity placements and venture capital </p></div> 2012-07-22T06:39:59+00:00 2012-07-22T06:39:59+00:00 https://pharma.industry-focus.net/bulk-drug-manufacturing/241-indo-phyto-chemicals-to-expand-its-bulk-drug-unit-in-shakanpur-in-pirumadara.html Administrator [email protected]

<div class="feed-description"><p> Indo Phyto Chemicals is to expand its bulk drug unit in Shakanpur in Pirumadara in Nainital in Uttarakhand with an investment of Rs. 50 million. The project involves expanding its bulk drug unit to produce Estradiol, Levonorgestrel, Norethisterone, Allylestrenol, Lynestrenol, Nandrolone Decanoate, ThiopentalSodium, Spironolactone, Solnaftate,Disulfiram etc., and will have a total capacity of 140000 kg /year . </p> <p> Indo Phyto Chemicals Private Limited Village Shakhanpur, P.O. Pirumadara District Nainital, Uttarakhand- 244714. E-mail: [email protected]; Fax No.: 05947-282128; 282328 </p></div>

<div class="feed-description"><p> Indo Phyto Chemicals is to expand its bulk drug unit in Shakanpur in Pirumadara in Nainital in Uttarakhand with an investment of Rs. 50 million. The project involves expanding its bulk drug unit to produce Estradiol, Levonorgestrel, Norethisterone, Allylestrenol, Lynestrenol, Nandrolone Decanoate, ThiopentalSodium, Spironolactone, Solnaftate,Disulfiram etc., and will have a total capacity of 140000 kg /year . </p> <p> Indo Phyto Chemicals Private Limited Village Shakhanpur, P.O. Pirumadara District Nainital, Uttarakhand- 244714. E-mail: [email protected]; Fax No.: 05947-282128; 282328 </p></div> 2012-07-22T06:39:28+00:00 2012-07-22T06:39:28+00:00 https://pharma.industry-focus.net/bulk-drug-manufacturing/240-infinity-laboratories-to-set-up-api-unit-in-behra.html Administrator [email protected]

<div class="feed-description"><p> Infinity Laboratories Ltd to set up a active pharmaceuticals ingredient units in Behra village in Derabassi in Mohali district of Punjab. The project cost is estimated at Rs. 95 million and will produce Hydroxy phenyl glycine Dane Salt (478 tpa), Cefuroxime acid (66 tpa) and will produce sodium sulphate as by product (235 tpa). </p> <p> Infinity Laboratories Private Limited H.No. 1080, Sector-12-A, Panchkula, Haryana E-mail: [email protected] </p></div>

<div class="feed-description"><p> Infinity Laboratories Ltd to set up a active pharmaceuticals ingredient units in Behra village in Derabassi in Mohali district of Punjab. The project cost is estimated at Rs. 95 million and will produce Hydroxy phenyl glycine Dane Salt (478 tpa), Cefuroxime acid (66 tpa) and will produce sodium sulphate as by product (235 tpa). </p> <p> Infinity Laboratories Private Limited H.No. 1080, Sector-12-A, Panchkula, Haryana E-mail: [email protected] </p></div> 2012-07-22T06:40:47+00:00 2012-07-22T06:40:47+00:00 https://pharma.industry-focus.net/bulk-drug-manufacturing/243-cks-pharma-labs-to-set-up-bulk-drug-unit-in-jaggayapet.html Administrator [email protected]

<div class="feed-description"><p> CKS Pharma Labs Pvt Ltd to set up a bulk drug unit in Jaggayapet in Krishna district of Andhra Pradesh with an investment of Rs. 42 million. The project involves setting up of a bulk drug unit to produce Pantoprazole Sodium, Carvedilol, Lansoprazole,Prasugrel Hydrochloride, LevoCetrizine Dihydrochloride, Lamotrigine, Lamivudine, Fluconazole etc., and will have a total capacity of 15.20 mtpm. </p> <p> CKS Pharma Labs H. No. 6-980, Shop No.1, Opposite to NSP Canal Office Hyderabad Road, Jagayyapet - 521175 District Krishna, Andhra Pradesh. E-mail: [email protected] </p></div>

<div class="feed-description"><p> CKS Pharma Labs Pvt Ltd to set up a bulk drug unit in Jaggayapet in Krishna district of Andhra Pradesh with an investment of Rs. 42 million. The project involves setting up of a bulk drug unit to produce Pantoprazole Sodium, Carvedilol, Lansoprazole,Prasugrel Hydrochloride, LevoCetrizine Dihydrochloride, Lamotrigine, Lamivudine, Fluconazole etc., and will have a total capacity of 15.20 mtpm. </p> <p> CKS Pharma Labs H. No. 6-980, Shop No.1, Opposite to NSP Canal Office Hyderabad Road, Jagayyapet - 521175 District Krishna, Andhra Pradesh. E-mail: [email protected] </p></div> 2010-06-01T07:12:22+00:00 2010-06-01T07:12:22+00:00 https://pharma.industry-focus.net/usfda-approvals/213-astral-pharma-receives-usfda-approval-for-vadodara-plant.html Administrator [email protected]

<div class="feed-description"><br />Astral Pharma which manufactures sterile antibiotic powder injectables at Makrarpura in Vadodara in Gujarat has received USFDA approval, which facilitates the company to market its product in USA. The company has already received approvals from HPFBI-Canada, TGA-Australia, MCC-South Africa and ANVISA-Brazil. It has entered into strategic business tie up with Sagent Pharmaceutical Inc with whom more than 15 Abbreviated New Drug Application (ANDAs) have been filled for US market.  At Makarpura, the company has two manufacturing facilities- one for Semi Synthetic Penicillin group and other for cephlasporin group.</div>

<div class="feed-description"><br />Astral Pharma which manufactures sterile antibiotic powder injectables at Makrarpura in Vadodara in Gujarat has received USFDA approval, which facilitates the company to market its product in USA. The company has already received approvals from HPFBI-Canada, TGA-Australia, MCC-South Africa and ANVISA-Brazil. It has entered into strategic business tie up with Sagent Pharmaceutical Inc with whom more than 15 Abbreviated New Drug Application (ANDAs) have been filled for US market.  At Makarpura, the company has two manufacturing facilities- one for Semi Synthetic Penicillin group and other for cephlasporin group.</div> 2010-02-19T05:58:04+00:00 2010-02-19T05:58:04+00:00 https://pharma.industry-focus.net/industry-overview/210-drreddy-laboratories-to-focus-on-domestic-sales.html Administrator [email protected]

<div class="feed-description">Dr.Reddy Laboratories which has been ranked 13th in terms of domestic sales is bringing its focus to improve its ranking. The company had been amongst the top ten few years back and lost it due to lack of focus. It plans to launch new therapeutic products in popular segments like cardiovascular, dermatology and diabetes and plans to strengthen its northern and eastern markets. The current Indian domestic market is estimated at Rs. 550,000 million and Dr.Reddys have a 2.7 % market share.</div>

<div class="feed-description">Dr.Reddy Laboratories which has been ranked 13th in terms of domestic sales is bringing its focus to improve its ranking. The company had been amongst the top ten few years back and lost it due to lack of focus. It plans to launch new therapeutic products in popular segments like cardiovascular, dermatology and diabetes and plans to strengthen its northern and eastern markets. The current Indian domestic market is estimated at Rs. 550,000 million and Dr.Reddys have a 2.7 % market share.</div>